SUPN - Despite 1 Major Headwind and Pricey Shares This Stock Is Still a Buy
2023-06-10 07:40:00 ET
Supernus Pharmaceuticals ' (NASDAQ: SUPN) stock price is up 24% over the last 12 months, suggesting investors are still keen on buying it despite its high valuation and some stiff pressure it's getting on its revenue. What could be driving stock traders to bid up its shares when they already seem pricey and near-term performance looks mixed at best?
Let's investigate, and in doing so try to figure out what makes this stock so purchase-worthy despite its issues.
Supernus' claim to fame is its longtime work developing medicines for central nervous system (CNS) conditions like attention deficit hyperactivity disorder (ADHD) and epilepsy. Over the past 10 years, its portfolio expanded consistently, and it now has eight medicines on the market. In that period its quarterly net income soared by 429%, arriving just short of $17 million, delighting shareholders in the process.
For further details see:
Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy